<DOC>
	<DOCNO>NCT00394836</DOCNO>
	<brief_summary>A Single-Arm , International , Multi-Center Trial HuMax-CD20 ( Ofatumumab ) , Fully Human Monoclonal Anti-CD20 Antibody , Patients With Follicular Lymphoma Who Are Refractory Rituximab Monotherapy Combination With Chemotherapy</brief_summary>
	<brief_title>HuMax-CD20 ( Ofatumumab ) n Follicular Lymphoma ( FL ) Patients Refractory Rituximab</brief_title>
	<detailed_description>Patients study randomize two dose group . Patients dose group receive one infusion 300 mg HuMax-CD20 follow 7 weekly infusion either 500 1000 mg HuMax-CD20 . Disease status assess every 3 month month 24 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Patient follicular lymphoma grade 1 2 Refractory rituximab give monotherapy combination chemotherapy rituximab give maintenance treatment follow Rchemo , define : failure achieve least PR rituximab give monotherapy combination chemotherapy ; , disease progression rituximab ( either give monotherapy combination chemotherapy rituximab maintenance treatment follow Rchemo ) ; , disease progression responder within 6 month last dose rituximab ( either give monotherapy combination chemotherapy rituximab maintenance treatment schedule follow Rchemo ) Tumor verify CD20+ positive excisional lymph node biopsy CT scan screening phase ( base local evaluation ) showing : 2 clearly demarcated lesion large diameter ≥ 1.5 cm , 1 clearly demarcate lesion large diameter ≥ 2,0 cm ECOG Performance Status 0 , 1 , 2 Age ≥ 18 year Following receipt verbal write information study , patient must provide sign informed consent study related activity carry Exclusion Criteria Previous autologous stem cell transplantation within 6 month Previous allogeneic stem cell transplantation More 1 previous radio immunotherapy regimen Received radio immunotherapy within 3 month Received Anticancer treatment within 4 week Received monoclonal antibody , rituximab within 3 month Patients previously treat antiCD20 monoclonal antibody , rituximab Life expectancy le 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>ofatumumab</keyword>
	<keyword>rituximab</keyword>
	<keyword>NHL</keyword>
	<keyword>CD20</keyword>
	<keyword>refractory</keyword>
</DOC>